Cobalamin A (cblA) and B (cblB) Defects
What is Cobalamin A (cblA) and B (cblB) Defects?
Cobalamin A and B defects are rare inherited metabolic disorders that affect how the body processes vitamin B12. These genetic conditions prevent cells from converting vitamin B12 into adenosylcobalamin, a form the body needs for specific chemical reactions.
When adenosylcobalamin cannot be made properly, a substance called methylmalonic acid builds up in the blood and urine. This buildup can damage organs and tissues if left untreated. The condition is present from birth and requires lifelong monitoring and treatment.
Both cblA and cblB defects cause isolated methylmalonic aciduria, meaning only methylmalonic acid levels are elevated. Unlike some other B12 disorders, these conditions do not affect homocysteine levels. Early detection through newborn screening or blood testing helps prevent serious complications.
Symptoms
- Poor feeding and difficulty gaining weight in infants
- Vomiting and dehydration
- Weak muscle tone or floppiness
- Developmental delays in reaching milestones
- Lethargy or extreme tiredness
- Breathing problems
- Seizures in severe cases
- Enlarged liver
- Failure to thrive
- Metabolic crisis episodes during illness or stress
Some children with milder forms may show few symptoms early in life. However, metabolic stress from illness or fasting can trigger sudden severe episodes. Early diagnosis before symptoms appear leads to better long-term outcomes.
Concerned about Cobalamin A (cblA) and B (cblB) Defects? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Cobalamin A and B defects are caused by mutations in specific genes that control vitamin B12 processing. CblA defects result from mutations in the MMAA gene, while cblB defects come from mutations in the MMAB gene. These genes provide instructions for making proteins needed to convert vitamin B12 into adenosylcobalamin.
The condition is inherited in an autosomal recessive pattern. This means a child must inherit one mutated gene copy from each parent to develop the disorder. Parents who carry one mutated copy typically have no symptoms themselves. When both parents are carriers, each child has a 25 percent chance of being affected. Family history and consanguinity increase the risk of these rare genetic conditions.
How it's diagnosed
Cobalamin A and B defects are diagnosed through blood and urine tests that measure methylmalonic acid levels. Elevated MMA in blood or urine indicates a problem with B12 processing. Many cases are identified through newborn screening programs that test for metabolic disorders in the first days of life.
Genetic testing confirms the diagnosis by identifying mutations in the MMAA or MMAB genes. Additional tests help determine the specific type of B12 defect and rule out other causes of high methylmalonic acid. Rite Aid offers methylmalonic acid testing as an add-on to our preventive health panel, making it easier to monitor this condition once diagnosed. Testing through our Quest Diagnostics lab network provides convenient access to specialized metabolic screening.
Treatment options
- Vitamin B12 injections in high doses to bypass the metabolic defect
- Low-protein diet to reduce methylmalonic acid production
- Special medical formulas free of certain amino acids
- Carnitine supplements to help remove toxic substances
- Regular monitoring of blood MMA levels
- Increased fluids during illness to prevent metabolic crisis
- Emergency protocols for fever, vomiting, or infection
- Genetic counseling for families
- Coordination with metabolic specialists
- Nutritional support from dietitians trained in metabolic disorders
Need testing for Cobalamin A (cblA) and B (cblB) Defects? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Both cblA and cblB defects prevent the body from making adenosylcobalamin from vitamin B12, but they involve mutations in different genes. CblA defects involve the MMAA gene, while cblB defects involve the MMAB gene. The symptoms and treatment are similar for both conditions, though the specific genetic cause differs.
These genetic conditions cannot be cured because they result from permanent changes in DNA. However, early treatment with high-dose vitamin B12 injections and dietary management can prevent most complications. Many patients live healthy lives with proper lifelong treatment and monitoring.
Testing frequency depends on age and disease control. Infants and young children typically need monthly or quarterly testing to adjust treatment. Once stable, adults may need testing every 3 to 6 months or more frequently during illness.
High doses of vitamin B12 given through injections can partially overcome the genetic defect by flooding the system with substrate. While the enzymes still do not work perfectly, providing excess B12 allows some adenosylcobalamin to be made. This reduces methylmalonic acid buildup enough to prevent serious complications in many patients.
Common triggers include infections, fever, vomiting, fasting, or eating too much protein. During these times, the body breaks down more protein and produces more methylmalonic acid. Illness also increases metabolic demands, making the existing enzyme defect more problematic and potentially leading to dangerous acid buildup.
No, these are different conditions. B12 deficiency means not getting enough vitamin B12 from diet or having absorption problems. Cobalamin defects are genetic disorders where the body cannot process B12 properly even when levels are normal. People with cblA or cblB defects need much higher B12 doses than those with simple deficiency.
Protein-rich foods must be carefully controlled because they contain amino acids that produce methylmalonic acid when broken down. This includes meat, fish, eggs, dairy, beans, and nuts. A metabolic dietitian creates individualized meal plans that provide enough protein for growth while keeping MMA levels safe.
While cobalamin defects are present from birth, some people with milder forms may not show symptoms until adolescence or adulthood. Stress, illness, pregnancy, or dietary changes can unmask the condition. Adults may experience fatigue, confusion, kidney problems, or pancreatitis as first symptoms.
Newborn screening can detect many cases by measuring markers like C3 acylcarnitine or methylmalonic acid in dried blood spots. However, some mild cases may be missed. Follow-up testing with more specific MMA measurement and genetic testing is needed to confirm the diagnosis and determine the exact type of defect.
Untreated cobalamin A and B defects can cause intellectual disability, kidney failure, pancreatitis, and movement disorders. Repeated metabolic crises can lead to permanent brain damage. Some patients develop vision problems or bone marrow suppression. Early diagnosis and consistent treatment prevent most of these serious complications.